Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Allergan Rises Most in Year as Botox Sales Lift Profit

Allergan Inc. climbed the most in almost a year after second-quarter earnings beat analyst estimates and the company raised the lower end of its full-year forecast.

Allergan rose 4.3 percent to close at $85.62 in New York, the biggest increase since Aug. 23, 2011. Earnings excluding some items of $1.07 a share beat by 1 cent the average of 22 analyst estimates compiled by Bloomberg.

Earnings for 2012 will be $4.15 to $4.19 a share, the company said, increasing the lower end of the outlook by 2 cents. Botox sales increased 10 percent to $461.2 million in the second quarter, while revenue from southern Europe wasn’t hurt by the debt crisis, the company said.

“We have just some fabulous growth rates, even in the so-called old Europe,” David Pyott, Allergan’s CEO, said on a conference call with analysts.

Allergan has more than half the European breast implant market share, which is split among 11 companies, Pyott said in a telephone interview. Worldwide sales growth for Allergan’s implants has been 14 percent in this year, he said.

The company’s sales benefited after French and German officials in December recommended that women have surgery to remove faulty implants made by Poly Implant Prothese SA of France. Women sought Allergan’s products as replacements, Pyott said.

“The market doesn’t seem to have taken a hit, despite what one would think would be negative perceptions,” Pyott said.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.